At a glance
ClinicalIndex Comparison RecordN/ACompleted· 2,004 enrolled
Drug / intervention
GuardantSHIELD Blood Testother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of Colorectal Cancer Screening Options
In Brief
A clinical study evaluating GuardantSHIELD Blood Test for Colon Cancer. Completed, enrolled 2,004 participants across 1 site.
Detailed Summary
The investigators propose to evaluate Guardant Health's commercially available colorectal cancer screening assay(Guardant SHIELD) in individuals who are not up to date with CRC screening.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColon Cancer
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2023202420252026
Enrollment StartMar 2022
Primary CompletionDec 2022
Study CompletionJun 2023
First PostedAug 2023
TodayJul 2026
First PostedAug 14, 2023
Enrollment StartMar 17, 2022
Primary CompletionDec 31, 2022
Study CompletionJun 15, 2023
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 2.9 years ago
Interventions
GuardantSHIELD Blood Testother
The GuardantSHIELD CRC screening test is a commercially available test which works by finding signs of colorectal tumor in the blood of patients at average risk for CRC